PURPOSE: Intensity of end-of-life care receives much attention in oncology because of concerns that high-intensity care is inconsistent with patient goals, leads to worse caregiver outcomes, and is expensive. Little is known about such care in those undergoing allogeneic hematopoietic cell transplantation (HCT), a population at high risk for morbidity and mortality. PATIENTS AND METHODS: We conducted a population-based analysis of patients who died between 2000 and 2013, within 1 year of undergoing an inpatient allogeneic HCT using California administrative data. Previously validated markers of intensity were examined and included: hospital death, intensive care unit (ICU) admission, and procedures such as intubation and cardiopulmonary resuscitation at end of life. Multivariable logistic regression models determined clinical and sociodemographic factors associated with: hospital death, a medically intense intervention (ICU admission, cardiopulmonary resuscitation, hemodialysis, intubation), and ≥ two intensity markers. RESULTS: Of the 2,135 patients in the study population, 377 were pediatric patients (age ≤ 21 years), 461 were young adults (age 22 to 39 years), and 1,297 were adults (age ≥ 40 years). The most common intensity markers were: hospital death (83%), ICU admission (49%), and intubation (45%). Medical intensity varied according to age, underlying diagnosis, and presence of comorbidities at time of HCT. Patients with higher-intensity end-of-life care included patients age 15 to 21 years and 30 to 59 years, patients with acute lymphoblastic leukemia, and those with comorbidities at time of HCT. CONCLUSION: Patients dying within 1 year of inpatient allogeneic HCT are receiving medically intense end-of-life care with variations related to age, underlying diagnosis, and presence of comorbidities at time of HCT. Future studies need to determine if these patterns are consistent with patient and family goals.
PURPOSE: Intensity of end-of-life care receives much attention in oncology because of concerns that high-intensity care is inconsistent with patient goals, leads to worse caregiver outcomes, and is expensive. Little is known about such care in those undergoing allogeneic hematopoietic cell transplantation (HCT), a population at high risk for morbidity and mortality. PATIENTS AND METHODS: We conducted a population-based analysis of patients who died between 2000 and 2013, within 1 year of undergoing an inpatient allogeneic HCT using California administrative data. Previously validated markers of intensity were examined and included: hospital death, intensive care unit (ICU) admission, and procedures such as intubation and cardiopulmonary resuscitation at end of life. Multivariable logistic regression models determined clinical and sociodemographic factors associated with: hospital death, a medically intense intervention (ICU admission, cardiopulmonary resuscitation, hemodialysis, intubation), and ≥ two intensity markers. RESULTS: Of the 2,135 patients in the study population, 377 were pediatric patients (age ≤ 21 years), 461 were young adults (age 22 to 39 years), and 1,297 were adults (age ≥ 40 years). The most common intensity markers were: hospital death (83%), ICU admission (49%), and intubation (45%). Medical intensity varied according to age, underlying diagnosis, and presence of comorbidities at time of HCT. Patients with higher-intensity end-of-life care included patients age 15 to 21 years and 30 to 59 years, patients with acute lymphoblastic leukemia, and those with comorbidities at time of HCT. CONCLUSION:Patients dying within 1 year of inpatient allogeneic HCT are receiving medically intense end-of-life care with variations related to age, underlying diagnosis, and presence of comorbidities at time of HCT. Future studies need to determine if these patterns are consistent with patient and family goals.
Authors: Craig C Earle; Elyse R Park; Bonnie Lai; Jane C Weeks; John Z Ayanian; Susan Block Journal: J Clin Oncol Date: 2003-03-15 Impact factor: 44.544
Authors: Elizabeth T Loggers; Paul K Maciejewski; Rachel Jimenez; Matthew Nilsson; Elizabeth Paulk; Heather Stieglitz; Holly G Prigerson Journal: J Palliat Med Date: 2013-09-20 Impact factor: 2.947
Authors: Oreofe O Odejide; Diana Y Salas Coronado; Corey D Watts; Alexi A Wright; Gregory A Abel Journal: J Oncol Pract Date: 2014-10-07 Impact factor: 3.840
Authors: Emily E Johnston; Elysia Alvarez; Olga Saynina; Lee M Sanders; Smita Bhatia; Lisa J Chamberlain Journal: Cancer Date: 2018-02-02 Impact factor: 6.860
Authors: Jennifer W Mack; Kun Chen; Francis P Boscoe; Foster C Gesten; Patrick J Roohan; Maria J Schymura; Deborah Schrag Journal: Med Care Date: 2015-12 Impact factor: 2.983
Authors: Sergio A Giralt; Charles F LeMaistre; Navneet S Majhail; Stephanie H Farnia; Paul A Carpenter; Richard E Champlin; Stephen Crawford; David I Marks; James L Omel; Paul J Orchard; Jeanne Palmer; Wael Saber; Bipin N Savani; Paul A Veys; Christopher N Bredeson Journal: Biol Blood Marrow Transplant Date: 2015-08-07 Impact factor: 5.742
Authors: Richard J Lin; Abigail G Cohen; Stacy M Stabler; Sean M Devlin; Theresa A Elko; Molly A Maloy; Beatriz Korc-Grodzicki; Koshy Alexander; Dana Kramer; Míriam Sanchez-Escamilla; Nerea Castillo Flores; Juliet N Barker; Christina Cho; Parastoo B Dahi; Boglarka Gyurkocza; Esperanza B Papadopoulos; Miguel-Angel Perales; Ioannis Politikos; Doris M Ponce; Craig S Sauter; Michael Scordo; Brian C Shaffer; Gunjan L Shah; Roni Tamari; James W Young; Ann A Jakubowski; Sergio A Giralt; Judith E Nelson Journal: J Palliat Med Date: 2020-03-27 Impact factor: 2.947
Authors: Jorge Garcia Borrega; Jan-Michel Heger; Matthias Kochanek; Dennis A Eichenauer; Philipp Koehler; Udo Holtick; Michael Hallek; Christof Scheid; Boris Böll; Alexander Shimabukuro-Vornhagen Journal: Ann Hematol Date: 2021-10-20 Impact factor: 3.673